Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.
J Neuroimmune Pharmacol. 2020 Mar;15(1):17-26. doi: 10.1007/s11481-019-09876-9. Epub 2019 Sep 3.
Melanoma is one of the most aggressive and less chemotherapy-responsive human cancers, representing a major public health issue worldwide. The early diagnosis still represents the best approach in order to reduce mortality, especially in advanced stages. Preclinical evidence, collected through several in vitro and in vivo models, has been accumulating about the pathophysiological involvement of β-adrenoceptors in melanoma progression. This involvement has been paralleled by the evidence that drugs blocking β-adrenoceptors (β-blockers) may have a relevant role in the treatment of melanoma and in the prevention of its progression. β-blockers are a class of drugs extensively used in clinical practice, not limited to cardiovascular therapeutics. Evidence collected through retrospective and prospective observational studies suggests that treatment with β-blockers, mainly propranolol, is able to delay melanoma progression. Although conclusive evidence is still lacking, current knowledge proposes β-blockers as an opportunity for antitumor treatment in melanoma. Clinical trials are needed in order to prove their claimed efficacy. Graphical Abstract.
黑色素瘤是最具侵袭性且对化疗反应较差的人类癌症之一，是全球范围内的重大公共卫生问题。早期诊断仍然是降低死亡率的最佳方法，尤其是在晚期。通过多种体外和体内模型收集的临床前证据表明，β-肾上腺素受体在黑色素瘤进展中的病理生理参与。这一参与伴随着证据表明，阻断β-肾上腺素受体的药物（β-阻滞剂）可能在黑色素瘤的治疗和预防其进展中具有重要作用。β-阻滞剂是一类在临床实践中广泛使用的药物，不仅限于心血管治疗。通过回顾性和前瞻性观察研究收集的证据表明，β-阻滞剂（主要是普萘洛尔）治疗能够延缓黑色素瘤的进展。尽管目前还缺乏确凿的证据，但现有知识将β-阻滞剂作为黑色素瘤抗肿瘤治疗的一种选择。需要进行临床试验以证明其声称的疗效。图表摘要。
